AzurRx BioPharma (NASDAQ: AZRX), a New York-based biopharmaceutical company specializing in the development of therapeutic proteins for the treatment of patients with gastrointestinal disorders, recently talked about its usage of porcine (pig) products in its production of pharmaceuticals and medicinals. Included in the discussion was a look at the disadvantages of such usage. AzurRx noted that pigs have been used for centuries in medical research and development; in fact, one study noted that pigs had been used in an estimated 20 medications and pharmaceuticals including six for the pancreas, which are of particular interest for AZRX. There are downsides to such usage, the company noted, including supply chain, concentration and purity issues. Because of these issues, AzurRx is hoping to develop synthetic replacement products. One of AZRX’s most promising treatments is MS1819, a lead product candidate being studied for the treatment of exocrine pancreatic insufficiency (“EPI”) associated with cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). The company is currently involved in several clinical trials for the drug, including two trial sites that were recently activated in Turkey. “We are truly pleased and encouraged by the interest in our expanding global Phase 2 Combination Trial,” AzurRx chief medical officer Dr. James Pennington stated in the press release. “The recently reported interim data suggests promising results, and the full data readout is expected in the second quarter of next year. Our investigators in Turkey have been extremely diligent in driving the startup of this trial in a very efficient and effective manner, and we look forward to our continued work with them.”
To view the full press release, visit https://ibn.fm/KjZmz
About AzurRx BioPharma Inc.
AzurRx BioPharma is a biopharmaceutical company specialized in the research and development of nonsystemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial and the combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in New York, NY, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
